Evidence map›Paper›PMID 26006007›Full record

ArticleNature biotechnology2015

Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting.

Huanhuan Joyce Chen, Jian Sun, Zhiliang Huang, Harry Hou, Myra Arcilla, Nikolai Rakhilin, Daniel J Joe, Jiahn Choi, Poornima Gadamsetty, Jeff Milsom and 18 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. A human vascularized microtumor model of patient-derived colorectal cancer recapitulates clinical disease.Translational research : the journal of laboratory and clinical medicine · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Self-contained, low-cost Body-on-a-Chip systems for drug development.Experimental biology and medicine (Maywood, N.J.) · 2017
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 3 institutions in 1 country.

Huanhuan Joyce Chen1] Department of Biomedical Engineering, Cornell University, Ithaca, New York, USA. [2] Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
Jian SunDepartment of Medicine, Weill Cornell Medical College, New York, New York, USA.
Zhiliang HuangDepartment of Medicine, Weill Cornell Medical College, New York, New York, USA.
Harry HouDepartment of Cell Biology, Albert Einstein College of Medicine, New York, New York, USA.
Myra ArcillaDepartment of Medicine, Weill Cornell Medical College, New York, New York, USA.
Nikolai RakhilinDepartment of Biomedical Engineering, Cornell University, Ithaca, New York, USA.
Daniel J JoeDepartment of Biomedical Engineering, Cornell University, Ithaca, New York, USA.ORCID 0000000219458236
Jiahn ChoiDepartment of Biomedical Engineering, Cornell University, Ithaca, New York, USA.
Poornima GadamsettyDepartment of Biomedical Engineering, Cornell University, Ithaca, New York, USA.
Jeff MilsomDepartment of Surgery, Weill Cornell Medical College, New York, New York, USA.
Govind NandakumarDepartment of Surgery, Weill Cornell Medical College, New York, New York, USA.
Randy LongmanDepartment of Medicine, Weill Cornell Medical College, New York, New York, USA.
Xi Kathy ZhouDepartment of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York, USA.ORCID 000000028942439X
Robert EdwardsDepartment of Pathology, University of California, Irvine, Irvine, California, USA.
Jonlin ChenSchool of Electrical and Computer Engineering, Cornell University, Ithaca, New York, USA.
Kai Yuan ChenSchool of Electrical and Computer Engineering, Cornell University, Ithaca, New York, USA.
Pengcheng Bu1] Department of Biomedical Engineering, Cornell University, Ithaca, New York, USA. [2] School of Electrical and Computer Engineering, Cornell University, Ithaca, New York, USA.
Lihua WangDepartment of Biomedical Engineering, Cornell University, Ithaca, New York, USA.
Yitian XuDepartment of Biomedical Engineering, Cornell University, Ithaca, New York, USA.
Robert MunroeCollege of Veterinary Medicine and Biological Sciences, Cornell University, Ithaca, New York, USA.
Christian AbratteCollege of Veterinary Medicine and Biological Sciences, Cornell University, Ithaca, New York, USA.
Andrew D MillerCollege of Veterinary Medicine and Biological Sciences, Cornell University, Ithaca, New York, USA.
Zeynep H Gümüş1] Department of Medicine, Weill Cornell Medical College, New York, New York, USA. [2] Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000000273642202
Michael ShulerDepartment of Biomedical Engineering, Cornell University, Ithaca, New York, USA.
Nozomi NishimuraDepartment of Biomedical Engineering, Cornell University, Ithaca, New York, USA.
Winfried EdelmannDepartment of Cell Biology, Albert Einstein College of Medicine, New York, New York, USA.
Xiling Shen1] Department of Biomedical Engineering, Cornell University, Ithaca, New York, USA. [2] School of Electrical and Computer Engineering, Cornell University, Ithaca, New York, USA.
Steven M LipkinDepartment of Medicine, Weill Cornell Medical College, New York, New York, USA.
Cornell University · USAlbert Einstein College of Medicine · USUniversity of California, Irvine · US

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI STEVEN C. ALMO · 1985 to 2026
$111.2M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024996 · NCRR · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2007 to 2011
$49.6M
Clinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0M
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
DNA MISMATCH REPAIR AND CANCER IN MURINE MODELSR01CA076329 · NCI · YESHIVA UNIVERSITY · PI EDELMANN, WINFRIED · 1998 to 2017
$6.9M
DNA Mismatch Repair and associated genes in suppression of GI adenomas and carcinR01CA098626 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LIPKIN, STEVEN M · 2004 to 2014
$2.9M
Microphysiologial systems and low cost microfluidic platform with analyticsUH2TR000516 · NCATS · CORNELL UNIVERSITY · PI HICKMAN, JAMES J, SHULER, MICHAEL L · 2012 to 2014
$2.9M
Multi-scale modeling of asymmetric cell divisionR01GM095990 · NIGMS · CORNELL UNIVERSITY · PI SHEN, XILING · 2011 to 2015
$1.5M
Robustness of the Intestinal Stem Cell NicheR01GM114254 · NIGMS · DUKE UNIVERSITY · PI SHEN, XILING · 2015 to 2017
$918k
The Function and Microbial Regulation of Innate Lymphoid Cells in IBDK08DK099381 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI LONGMAN, RANDY S · 2013 to 2017
$780k
Mismatch Repair and Associated Genes in Suppression of GI Adenomas and CarcinomasR56CA098626 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LIPKIN, STEVEN M · 2009 to 2009
$249k
NCATS NIH HHS UH2 TR000516NCATS NIH HHS UH2TR000516NCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR001414NCI NIH HHS CA098626NCI NIH HHS P30 CA013330NCI NIH HHS R01 CA076329NCI NIH HHS R01 CA098626NCI NIH HHS R56 CA098626NCRR NIH HHS 2UL1-RR024996NCRR NIH HHS UL1 RR024996NIDDK NIH HHS K08 DK099381NIGMS NIH HHS R01 GM095990NIGMS NIH HHS R01 GM114254
6 · The paper itself

Abstract

Current orthotopic xenograft models of human colorectal cancer (CRC) require surgery and do not robustly form metastases in the liver, the most common site clinically. CCR9 traffics lymphocytes to intestine and colorectum. We engineered use of the chemokine receptor CCR9 in CRC cell lines and patient-derived cells to create primary gastrointestinal (GI) tumors in immunodeficient mice by tail-vein injection rather than surgery. The tumors metastasize inducibly and robustly to the liver. Metastases have higher DKK4 and NOTCH signaling levels and are more chemoresistant than paired subcutaneous xenografts. Using this approach, we generated 17 chemokine-targeted mouse models (CTMMs) that recapitulate the majority of common human somatic CRC mutations. We also show that primary tumors can be modeled in immunocompetent mice by microinjecting CCR9-expressing cancer cell lines into early-stage mouse blastocysts, which induces central immune tolerance. We expect that CTMMs will facilitate investigation of the biology of CRC metastasis and drug screening.

Indexed as

Disease Models, AnimalAnimalsBlastocystCell Line, TumorColorectal NeoplasmsGene Expression Regulation, NeoplasticHumansIntercellular Signaling Peptides and ProteinsLiver Neoplasms, ExperimentalMiceNeoplasm MetastasisReceptors, CCRReceptors, NotchSignal TransductionXenograft Model Antitumor AssaysCC chemokine receptor 9DKK4 protein, humanIntercellular Signaling Peptides and ProteinsReceptors, CCRReceptors, Notch

Identifiers

PMID26006007
PMCPMC4532544
OpenAlexW1490689662

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.